GIP and GLP-1 receptor co-agonist

CT-388 7.5 mg injection once weekly

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

CT388_SC_7p5MG_QW

Mechanism: Dual incretin agonist (tirzepatide and others)
Trials: 1
Participants in these arms: 6

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Overweight or obesity without diabetes (adults)	Discontinuation due to adverse events	longest follow-up	Placebo	HR 0.70 (0.01 to 57.03)	0.64
Overweight or obesity without diabetes (adults)	Discontinuation due to gastrointestinal adverse events	longest follow-up	Placebo	HR 0.69 (0.01 to 56.51)	0.64

Trials

NCT04838405
A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus
2021 · 4 weeks

CT-388 7.5 mg injection once weekly

Related

Effects across outcomes

Trials